This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (25)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Multiple Sclerosis/ Demyelinating Disease  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Richard K. Burt, MD; Bruce Cohen, MD; John Rose, MD; Finn Petersen, MD; Yu Oyama, MD; Dusan Stefoski, MD; George Katsamakis, MD; Ewa Carrier, MD; Tomas Kozak, MD; Paolo A. Muraro, MD; Roland Martin, MD; Roger Hintzen, MD; Shimon Slavin, MD; Dimitrios Karussis, MD; Shalom Haggiag, MD; Julio C. Voltarelli, MD; George W. Ellison, MD; Borko Jovanovic, PhD; Uday Popat, MD; Joseph McGuirk, MD; Laisvyde Statkute, MD; Larissa Verda, PhD; Judith Haas, MD; Renate Arnold, MD

Arch Neurol. 2005;62:860-864.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Hematopoietic stem cell transplantation (HSCT) was proposed as a treatment for multiple sclerosis (MS) in 1995 based on favorable results in animal models including experimental autoimmune encephalomyelitis.¹ These initial or first-generation trials were developed by medical oncology subspecialists, used malignancy-specific myeloablative transplantation regimens, and selected patients with secondary progressive MS with rapid progression of disability. In general, these trials suffered from higher than anticipated toxic reactions including treatment-related and disease-related mortality, continued loss of . . . [Full Text of this Article]

RATIONALE OF HSCT

ANIMAL RESULTS

MOBILIZATION OF HSCs FROM PATIENTS WITH MS

EX VIVO HCS SELECTION

CONDITIONING REGIMEN

RESULTS OF FIRST-GENERATION HSCT PROTOCOLS FOR MS

SECOND-GENERATION NONMYELOABLATIVE HSCT PROTOCOLS FOR MS

SUMMARY

AUTHOR INFORMATION

Author Affiliations: Division of Immunotherapy, Departments of Medicine (Drs Burt, Oyama, Statkute, and Verda), Neurology (Dr Cohen), and Preventive Medicine (Dr Jovanovic), Northwestern University Feinberg School of Medicine, Chicago, Ill; Departments of Neurology and Medicine, University of Utah (Drs Rose and Petersen), Salt Lake City; Department of Neurology, Rush University Medical Center (Drs Stefoski and Katsamakis), Chicago; Departments of Medicine and Neurosciences, University of California, San Diego (Drs Carrier and Ellison); Department of Medicine, Charles University, Prague, Czech Republic (Dr Kozak); National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (Drs Muraro and Martin); Department of Neurology, Erasmus Medical Centre, Rotterdam, the Netherlands (Dr Hintzen); Departments of Bone Marrow Transplantation and Neurology, Hadassah University Hospital, Jerusalem, Israel (Drs Slavin, Karussis, and Haggiag); Department of Medicine, University of São Paolo, Ribeiro Preto, Brazil (Dr Voltarelli); Department of Blood and Marrow Transplantation, M. D. Anderson Cancer Center, Houston, Tex (Dr Popat); Kansas City Cancer Center, Kansas City, Mo (Dr McGuirk); and Department of Neurology, Jewish Hospital, and Department of Hematology and Oncology, Charité Hospital, Berlin, Germany (Drs Hass and Arnold).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation
Fagius et al.
Mult Scler 2009;15:229-237.
ABSTRACT  

Continued Disease Activity in a Patient With Multiple Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Lu et al.
Arch Neurol 2009;66:116-120.
ABSTRACT | FULL TEXT  

Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis
Mondria et al.
J. Neurol. Neurosurg. Psychiatry 2008;79:1013-1015.
ABSTRACT | FULL TEXT  

A Three-Year Study of Brain Atrophy after Autologous Hematopoietic Stem Cell Transplantation in Rapidly Evolving Secondary Progressive Multiple Sclerosis
Rocca et al.
Am. J. Neuroradiol. 2007;28:1659-1661.
ABSTRACT | FULL TEXT  

Correction of Celiac Disease After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia
Kline et al.
Pediatrics 2007;120:e1120-e1122.
ABSTRACT | FULL TEXT  

High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
Gladstone et al.
Arch Neurol 2006;63:1388-1393.
ABSTRACT | FULL TEXT  

Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network
de Kleer et al.
Blood 2006;107:1696-1702.
ABSTRACT | FULL TEXT  

Finding a less toxic stem cell therapy for multiple sclerosis
Burt
Blood 2005;106:1514-1515.
FULL TEXT